Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) major shareholder Growth N. V. Biotech bought 400,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 17th. The stock was acquired at an average cost of $2.34 per share, with a total value of $936,000.00. Following the completion of the acquisition, the insider now owns 8,517,839 shares of the company’s stock, valued at approximately $19,931,743.26. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Black Diamond Therapeutics Stock Down 1.2 %
NASDAQ BDTX opened at $2.10 on Friday. The company has a fifty day moving average of $3.06 and a two-hundred day moving average of $2.83. The firm has a market capitalization of $108.32 million, a price-to-earnings ratio of -0.92 and a beta of 2.47. Black Diamond Therapeutics, Inc. has a 52 week low of $1.22 and a 52 week high of $6.85.
Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last posted its quarterly earnings data on Friday, August 11th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.02. Equities research analysts anticipate that Black Diamond Therapeutics, Inc. will post -2.08 EPS for the current year.
Analyst Ratings Changes
Get Our Latest Report on Black Diamond Therapeutics
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of BDTX. Bellevue Group AG boosted its stake in shares of Black Diamond Therapeutics by 50.8% during the second quarter. Bellevue Group AG now owns 8,135,839 shares of the company’s stock valued at $41,086,000 after purchasing an additional 2,740,000 shares during the period. RA Capital Management L.P. boosted its stake in shares of Black Diamond Therapeutics by 36.1% during the second quarter. RA Capital Management L.P. now owns 3,525,754 shares of the company’s stock valued at $17,805,000 after purchasing an additional 935,850 shares during the period. BlackRock Inc. boosted its stake in shares of Black Diamond Therapeutics by 3.6% during the first quarter. BlackRock Inc. now owns 2,329,164 shares of the company’s stock valued at $6,452,000 after purchasing an additional 80,697 shares during the period. Artal Group S.A. boosted its stake in shares of Black Diamond Therapeutics by 24.3% during the second quarter. Artal Group S.A. now owns 2,046,517 shares of the company’s stock valued at $10,335,000 after purchasing an additional 400,000 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Black Diamond Therapeutics during the second quarter valued at $10,100,000.
Black Diamond Therapeutics Company Profile
Black Diamond Therapeutics, Inc, a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial.
Read More
- Five stocks we like better than Black Diamond Therapeutics
- How to Invest in Grocery Stores
- Institutions Buy Consumer Staples, is the Bottom in?
- What Are the U.K. Market Holidays? How to Invest and Trade
- Fastenal or Simpson Manufacturing: Which is the Better Buy?
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Can These 3 Semiconductor Stocks Outpace Nvidia’s Growth?
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
